How many drugs treat Deep venous thrombosis?

Drug Landscape tracks 10 marketed treatments for Deep venous thrombosis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/deep-venous-thrombosis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Deep venous thrombosis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Deep venous thrombosis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Deep venous thrombosis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Dabigatran Etexilate	DABIGATRAN	Boehringer Ingelheim			2025-01-01
Xarelto	rivaroxaban	Johnson & Johnson	Direct Factor Xa Inhibitor	Factor Xa (FXa)	2011-01-01
Arixtra	FONDAPARINUX	Mylan Ireland Ltd	Factor Xa Inhibitor	Coagulation factor X	2001-01-01
Lovenox (Preservative Free)	ENOXAPARIN SODIUM	Sanofi	Low Molecular Weight Heparin	Antithrombin-III	1993-01-01
Coumadin	warfarin	Generic (originally Wisconsin Alumni Research Foundation)	Vitamin K antagonist (anticoagulant)	Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7	1954-01-01
Heparin Sodium In Plastic Container	HEPARIN	Merck & Co.	Anti-coagulant	Antithrombin-III	1939-01-01
Heparin Sodium In Plastic Container	Heparin Sodium	Fresenius Kabi	Anticoagulant	Antithrombin III, Coagulation Factors Xa and IIa	1939-01-01
Xarelto	Xarelto	University Hospital, Montpellier		Suppressor of tumorigenicity 14 protein, Coagulation factor X, Coagulation factor X
nadroparin	nadroparin	Onze Lieve Vrouwe Gasthuis
Lovenox	Lovenox	University of Monastir		Antithrombin-III

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 1 drug in Deep venous thrombosis
Boehringer Ingelheim · 1 drug in Deep venous thrombosis
Dana-Farber Cancer Institute · 1 drug in Deep venous thrombosis
Fresenius Kabi · 1 drug in Deep venous thrombosis
Generic (originally Wisconsin Alumni Research Foundation) · 1 drug in Deep venous thrombosis
Johnson & Johnson · 1 drug in Deep venous thrombosis
Leiden University Medical Center · 1 drug in Deep venous thrombosis
LifeBridge Health · 1 drug in Deep venous thrombosis
Merck & Co. · 1 drug in Deep venous thrombosis
Mylan Ireland Ltd · 1 drug in Deep venous thrombosis
Onze Lieve Vrouwe Gasthuis · 1 drug in Deep venous thrombosis
Pfizer · 1 drug in Deep venous thrombosis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Deep venous thrombosis:

Cite this brief

Drug Landscape (2026). Deep venous thrombosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/deep-venous-thrombosis. Accessed 2026-06-10.

Deep venous thrombosis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing